[HTML][HTML] Ocular therapeutics and molecular delivery strategies for neovascular age-related macular degeneration (Namd)
A Sarkar, V Junnuthula, S Dyawanapelly - International Journal of …, 2021 - mdpi.com
Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric
population. Intravitreal (IVT) injections are popular clinical option. Biologics and small …
population. Intravitreal (IVT) injections are popular clinical option. Biologics and small …
Predictors of visual acuity after treatment of neovascular age-related macular degeneration–current perspectives
LT Phan, GK Broadhead, TH Hong… - Clinical …, 2021 - Taylor & Francis
Visual acuity is a key outcome measure in the treatment of neovascular age-related macular
degeneration (nAMD) using anti-vascular endothelial growth factor agents. Large variations …
degeneration (nAMD) using anti-vascular endothelial growth factor agents. Large variations …
[HTML][HTML] Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular …
TA Ciulla, RM Hussain, D Taraborelli, JS Pollack… - Ophthalmology …, 2022 - Elsevier
Purpose The clinical practice visual acuity (VA) outcomes of anti-VEGF therapy for up to 5
years were assessed in patients with neovascular age-related macular degeneration …
years were assessed in patients with neovascular age-related macular degeneration …
[HTML][HTML] Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years
Introduction Randomised controlled trials provide evidence that a treatment works. Real
world evidence is required to assess if proven treatments are effective in practice. Method …
world evidence is required to assess if proven treatments are effective in practice. Method …
[HTML][HTML] Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration
R Lukacs, M Schneider, ZZ Nagy, GL Sandor… - BMC …, 2023 - Springer
Background Anti-vascular endothelial growth factor (VEGF) therapy is currently the most
effective therapy of exudative age-related macular degeneration (AMD). The aim of this …
effective therapy of exudative age-related macular degeneration (AMD). The aim of this …
[HTML][HTML] Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission
HJ Cho, YJ Jeon, W Yoon, J Yoon, J Kim, JW Kim - Scientific Reports, 2022 - nature.com
We investigated the characteristics of neovascular age-related macular degeneration
(AMD), which rarely recurs after initial remission. This study retrospectively analyzed 392 …
(AMD), which rarely recurs after initial remission. This study retrospectively analyzed 392 …
[HTML][HTML] Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration
R Jones, IM Stratton, PH Scanlon, S Theodoropoulou - Eye, 2023 - nature.com
Abstract Background/Objectives Timely assessment and treatment of patients with
neovascular AMD (nAMD) are crucial to preservation of vision. Loss to follow up (LTFU) in …
neovascular AMD (nAMD) are crucial to preservation of vision. Loss to follow up (LTFU) in …
[HTML][HTML] Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor …
HJ Cho, MY Song, W Yoon, J Yoon, SK Na, J Lee… - Scientific Reports, 2022 - nature.com
We investigated the characteristics of neovascular age-related macular degeneration (AMD)
in which exudation predominantly occurs as a subretinal fluid (SRF) during anti-vascular …
in which exudation predominantly occurs as a subretinal fluid (SRF) during anti-vascular …
Genome-wide analysis of genetic pleiotropy and causal genes across three age-related ocular disorders
X Yao, H Yang, H Han, X Kou, Y Jiang, M Luo, Y Zhou… - Human Genetics, 2023 - Springer
Age-related macular degeneration (AMD), cataract, and glaucoma are leading causes of
blindness worldwide. Previous genome-wide association studies (GWASs) have revealed a …
blindness worldwide. Previous genome-wide association studies (GWASs) have revealed a …
[HTML][HTML] The first-year variation in central retinal thickness predicts legal blindness in patients with neovascular age-related macular degeneration
Introduction: Due to its progressive nature, early evaluation and timely prediction of legal
blindness are important in patients with neovascular age-related macular degeneration …
blindness are important in patients with neovascular age-related macular degeneration …